Rate My Professor Bronwen Mayo

Dr Bronwen Mayo is a Lecturer in the School of Pharmacy and Biomedical Sciences within the College of Health at Adelaide University. She possesses a strong background in microbiology and toxicology pertaining to cancer treatment and completed her PhD in partnership with Helsinn Healthcare, focusing on the effects of naturally occurring gut peptides on cancer treatment toxicities. Since 2015, she has taught as a Lecturer in Biomedical Sciences at the University of South Australia College of Health and Human Services, which has transitioned into her current role at Adelaide University. Dr Mayo maintains a dedicated role in Academic Integrity, passionately educating students on the critical importance of upholding ethical standards throughout their programs in allied and clinical health areas. Her teaching strengths encompass digestive physiology. Additionally, she has actively promoted science within the community, serving as a committee member for the Australian Society for Medical Research from 2009.

Dr Mayo's research centers on cancer treatment-induced alimentary mucosal injury, or mucositis, with a particular emphasis on gut peptide interventions to alleviate the gastrointestinal toxicities arising from chemotherapy and targeted therapies. Her investigations explore impacts on the local mucosal environment, molecular alterations, and alterations in bacterial populations within the microbiome. Key publications include Mayo, B. et al. (2020), 'The GLP-2 Analogue Elsiglutide Reduces Diarrhoea Caused by the Tyrosine Kinase Inhibitor Lapatinib in Rats,' Cancer Chemotherapy and Pharmacology; Secombe, K.R. et al. (2020), 'Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome,' Integrative Cancer Therapies; Elad, S. et al. (2020), MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy, Cancer; Mayo, B. et al. (2017), 'Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues,' Cancer Chemotherapy and Pharmacology; Bowen, J.M. et al. (2019), 'Systematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelines,' Supportive Care in Cancer; and Vanhoecke, B. et al. (2015), 'Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art,' Experimental Biology and Medicine. She has also contributed to conference presentations on microbial changes and DNA damage in mucositis models. These efforts have supported advancements in preclinical modeling and clinical guidelines for oncology supportive care.